[Update on current care guidelines: multiple sclerosis]

Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. Patients with clinically isolated syndrome and at high-risk for RRMS are followed by magnetic resonance imaging to confirm the diagnosis of RRMS as early as possible. Interferon-beta and glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, fingolimod or natalizumab may be considered as second-line therapies. IMD is discontinued upon the transition of RRMS to secondary progressive phase.